Generali Investments Towarzystwo Funduszy Inwestycyjnych Sells 100 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Generali Investments Towarzystwo Funduszy Inwestycyjnych decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 8.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,150 shares of the specialty pharmaceutical company’s stock after selling 100 shares during the period. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Jazz Pharmaceuticals were worth $142,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. CWA Asset Management Group LLC bought a new position in Jazz Pharmaceuticals during the 3rd quarter worth $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Centre Asset Management LLC bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $9,335,000. Moloney Securities Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth about $464,000. Finally, Pacer Advisors Inc. raised its position in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after acquiring an additional 278,465 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ:JAZZ opened at $143.27 on Friday. The stock has a market cap of $8.66 billion, a price-to-earnings ratio of 20.18, a PEG ratio of 1.04 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The business’s 50 day moving average is $125.87 and its 200 day moving average is $118.62.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the transaction, the chief executive officer now owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. The trade was a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 5,053 shares of company stock valued at $617,442 over the last 90 days. Insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on JAZZ shares. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Piper Sandler reiterated an “overweight” rating and issued a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday. TD Cowen lowered their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Needham & Company LLC lifted their target price on Jazz Pharmaceuticals from $205.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. lifted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $182.47.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.